Home Semiconductor & Electronics Electronic Components Dopamine Agonists Market

Dopamine Agonists Market Size, Share & Trends Analysis Report By Indication (Parkinson's disease, Restless legs syndrome, Hyperprolactinemia, Others), By Drug Type (Ergot Alkaloids, Non-Ergot Dopamine Agonists), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Other Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Dopamine Agonists Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Parkinson's disease
    2. Restless legs syndrome
    3. Hyperprolactinemia
    4. Others
  2. Dopamine Agonists Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Ergot Alkaloids
    2. Non-Ergot Dopamine Agonists
  3. Dopamine Agonists Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Injectable
    3. Others
  4. Dopamine Agonists Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Other Pharmacies
  5. Regional Dopamine Agonists Market
    1. North America
      1. North America Dopamine Agonists Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      2. North America Dopamine Agonists Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      3. North America Dopamine Agonists Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      4. North America Dopamine Agonists Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
      5. U.S.
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      6. Canada
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
    2. Europe
      1. Europe Dopamine Agonists Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      2. Europe Dopamine Agonists Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      3. Europe Dopamine Agonists Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      4. Europe Dopamine Agonists Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
      5. U.K.
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      6. Germany
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      7. France
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      8. Spain
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      9. Italy
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      10. Russia
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      11. Nordic
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      12. Benelux
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      13. Rest of Europe
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
    3. APAC
      1. APAC Dopamine Agonists Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      2. APAC Dopamine Agonists Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      3. APAC Dopamine Agonists Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      4. APAC Dopamine Agonists Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
      5. China
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      6. Korea
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      7. Japan
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      8. India
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      9. Australia
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      10. Taiwan
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      11. South East Asia
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      12. Rest of Asia-Pacific
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Dopamine Agonists Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      2. Middle East and Africa Dopamine Agonists Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      3. Middle East and Africa Dopamine Agonists Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      4. Middle East and Africa Dopamine Agonists Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
      5. UAE
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      6. Turkey
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      7. Saudi Arabia
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      8. South Africa
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      9. Egypt
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      10. Nigeria
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      11. Rest of MEA
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
    5. LATAM
      1. LATAM Dopamine Agonists Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
      2. LATAM Dopamine Agonists Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Ergot Alkaloids
        2. Non-Ergot Dopamine Agonists
      3. LATAM Dopamine Agonists Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      4. LATAM Dopamine Agonists Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Other Pharmacies
      5. Brazil
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      6. Mexico
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      7. Argentina
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      8. Chile
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      9. Colombia
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
      10. Rest of LATAM
        1. Parkinson's disease
        2. Restless legs syndrome
        3. Hyperprolactinemia
        4. Others
        5. Ergot Alkaloids
        6. Non-Ergot Dopamine Agonists
        7. Oral
        8. Injectable
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Other Pharmacies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.